Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

GlaxoSmithKline Consumer Healthcare Pakistan

KASE:GSKCH
Snowflake Description

Solid track record with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GSKCH
KASE
PKR23B
Market Cap
  1. Home
  2. PK
  3. Household
Company description

GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan. The last earnings update was 158 days ago. More info.


Add to Portfolio Compare Print
  • GlaxoSmithKline Consumer Healthcare Pakistan has significant price volatility in the past 3 months.
GSKCH Share Price and Events
7 Day Returns
1.2%
KASE:GSKCH
-2.1%
Asia Personal Products
10.5%
PK Market
1 Year Returns
-31.6%
KASE:GSKCH
-16.8%
Asia Personal Products
-23%
PK Market
GSKCH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GlaxoSmithKline Consumer Healthcare Pakistan (GSKCH) 1.2% -12.5% -18.3% -31.6% 68.9% -
Asia Personal Products -2.1% -5.6% -13.2% -16.8% 8.1% 3.3%
PK Market 10.5% -16.1% -23.9% -23% -41% -22.2%
1 Year Return vs Industry and Market
  • GSKCH underperformed the Personal Products industry which returned -16.8% over the past year.
  • GSKCH underperformed the Market in Pakistan which returned -23% over the past year.
Price Volatility
GSKCH
Industry
5yr Volatility vs Market

Value

 Is GlaxoSmithKline Consumer Healthcare Pakistan undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of GlaxoSmithKline Consumer Healthcare Pakistan to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for GlaxoSmithKline Consumer Healthcare Pakistan.

KASE:GSKCH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in PKR PKR 5.000000
Payout Ratio Company Filings (2019-09-30) 729.4%
Discount Rate (Cost of Equity) See below 22.3%
Perpetual Growth Rate 10-Year PK Government Bond Rate 11.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for KASE:GSKCH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PK Govt Bond Rate 11.4%
Equity Risk Premium S&P Global 13.7%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.6
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.596 (1 + (1- 30%) (2.97%))
0.688
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 11.38% + (0.8 * 13.68%)
22.32%

Discounted Cash Flow Calculation for KASE:GSKCH using Dividend Discount Model Model

The calculations below outline how an intrinsic value for GlaxoSmithKline Consumer Healthcare Pakistan is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

KASE:GSKCH Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= PKR5 / (22.32% - 11.38%)
PKR45.69
KASE:GSKCH Discount to Share Price
Calculation Result
Value per share (PKR) From above. PKR45.69
Current discount Discount to share price of PKR196.29
= -1 x (PKR196.29 - PKR45.69) / PKR45.69
-329.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of GlaxoSmithKline Consumer Healthcare Pakistan is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GlaxoSmithKline Consumer Healthcare Pakistan's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GlaxoSmithKline Consumer Healthcare Pakistan's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KASE:GSKCH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in PKR PKR9.54
KASE:GSKCH Share Price ** KASE (2020-04-06) in PKR PKR196.29
Asia Personal Products Industry PE Ratio Median Figure of 124 Publicly-Listed Personal Products Companies 20.32x
Pakistan Market PE Ratio Median Figure of 276 Publicly-Listed Companies 7.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GlaxoSmithKline Consumer Healthcare Pakistan.

KASE:GSKCH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KASE:GSKCH Share Price ÷ EPS (both in PKR)

= 196.29 ÷ 9.54

20.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GlaxoSmithKline Consumer Healthcare Pakistan is overvalued based on earnings compared to the Asia Personal Products industry average.
  • GlaxoSmithKline Consumer Healthcare Pakistan is overvalued based on earnings compared to the Pakistan market.
Price based on expected Growth
Does GlaxoSmithKline Consumer Healthcare Pakistan's expected growth come at a high price?
Raw Data
KASE:GSKCH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 20.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Personal Products Industry PEG Ratio Median Figure of 43 Publicly-Listed Personal Products Companies 2.34x
Pakistan Market PEG Ratio Median Figure of 27 Publicly-Listed Companies 0.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GlaxoSmithKline Consumer Healthcare Pakistan, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GlaxoSmithKline Consumer Healthcare Pakistan's assets?
Raw Data
KASE:GSKCH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in PKR PKR35.35
KASE:GSKCH Share Price * KASE (2020-04-06) in PKR PKR196.29
Asia Personal Products Industry PB Ratio Median Figure of 172 Publicly-Listed Personal Products Companies 1.59x
Pakistan Market PB Ratio Median Figure of 386 Publicly-Listed Companies 0.59x
KASE:GSKCH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KASE:GSKCH Share Price ÷ Book Value per Share (both in PKR)

= 196.29 ÷ 35.35

5.55x

* Primary Listing of GlaxoSmithKline Consumer Healthcare Pakistan.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GlaxoSmithKline Consumer Healthcare Pakistan is overvalued based on assets compared to the Asia Personal Products industry average.
X
Value checks
We assess GlaxoSmithKline Consumer Healthcare Pakistan's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. GlaxoSmithKline Consumer Healthcare Pakistan has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is GlaxoSmithKline Consumer Healthcare Pakistan expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKline Consumer Healthcare Pakistan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.2%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GlaxoSmithKline Consumer Healthcare Pakistan expected to grow at an attractive rate?
  • Unable to compare GlaxoSmithKline Consumer Healthcare Pakistan's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare GlaxoSmithKline Consumer Healthcare Pakistan's earnings growth to the Pakistan market average as no estimate data is available.
  • Unable to compare GlaxoSmithKline Consumer Healthcare Pakistan's revenue growth to the Pakistan market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KASE:GSKCH Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 12.2%
Asia Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
Pakistan Market Earnings Growth Rate Market Cap Weighted Average 15%
Pakistan Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KASE:GSKCH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PKR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KASE:GSKCH Past Financials Data
Date (Data in PKR Millions) Revenue Cash Flow Net Income *
2019-09-30 15,831 823 1,117
2019-06-30 15,856 109 1,220
2019-03-31 15,120 -190 973
2018-12-31 14,875 -415 1,075
2018-09-30 13,237 -155 1,059
2018-06-30 11,470 393 863
2018-03-31 10,276 380 829
2017-12-31 8,298 559 707
2017-09-30 8,217 716
2017-06-30 7,670 1,255
2017-03-31 6,300 893
2016-12-31 5,376 950 545

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if GlaxoSmithKline Consumer Healthcare Pakistan is high growth as no earnings estimate data is available.
  • Unable to determine if GlaxoSmithKline Consumer Healthcare Pakistan is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KASE:GSKCH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from GlaxoSmithKline Consumer Healthcare Pakistan Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KASE:GSKCH Past Financials Data
Date (Data in PKR Millions) EPS *
2019-09-30 9.54
2019-06-30 10.42
2019-03-31 8.31
2018-12-31 9.18
2018-09-30 9.48
2018-06-30 8.12
2018-03-31 8.21
2017-12-31 7.40
2017-09-30 7.50
2017-06-30 13.13
2017-03-31 10.68
2016-12-31 7.60

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GlaxoSmithKline Consumer Healthcare Pakistan will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Check out GlaxoSmithKline Consumer Healthcare Pakistan's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
  2. GlaxoSmithKline Consumer Healthcare Pakistan's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess GlaxoSmithKline Consumer Healthcare Pakistan's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GlaxoSmithKline Consumer Healthcare Pakistan has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has GlaxoSmithKline Consumer Healthcare Pakistan performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GlaxoSmithKline Consumer Healthcare Pakistan's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GlaxoSmithKline Consumer Healthcare Pakistan has delivered over 20% year on year earnings growth in the past 5 years.
  • GlaxoSmithKline Consumer Healthcare Pakistan's 1-year earnings growth is less than its 5-year average (5.5% vs 27.2%)
  • GlaxoSmithKline Consumer Healthcare Pakistan's earnings growth has exceeded the Asia Personal Products industry average in the past year (5.5% vs 2.7%).
Earnings and Revenue History
GlaxoSmithKline Consumer Healthcare Pakistan's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GlaxoSmithKline Consumer Healthcare Pakistan Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KASE:GSKCH Past Revenue, Cash Flow and Net Income Data
Date (Data in PKR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 15,831.24 1,116.94 2,827.38
2019-06-30 15,856.04 1,219.91 2,753.57
2019-03-31 15,119.99 973.13 2,679.50
2018-12-31 14,875.27 1,074.55 2,649.28
2018-09-30 13,237.25 1,059.00 2,668.35
2018-06-30 11,469.51 862.78 2,473.63
2018-03-31 10,276.28 828.77 2,301.81
2017-12-31 8,298.14 706.82 2,007.16
2017-09-30 8,217.02 716.38 1,958.11
2017-06-30 7,670.03 1,255.17 1,761.33
2017-03-31 6,299.69 893.35 1,391.92
2016-12-31 5,375.80 545.47 1,113.72
2015-12-31 -0.34 0.34

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • GlaxoSmithKline Consumer Healthcare Pakistan has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • GlaxoSmithKline Consumer Healthcare Pakistan used its assets more efficiently than the Asia Personal Products industry average last year based on Return on Assets.
  • GlaxoSmithKline Consumer Healthcare Pakistan has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess GlaxoSmithKline Consumer Healthcare Pakistan's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GlaxoSmithKline Consumer Healthcare Pakistan has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is GlaxoSmithKline Consumer Healthcare Pakistan's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GlaxoSmithKline Consumer Healthcare Pakistan's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GlaxoSmithKline Consumer Healthcare Pakistan is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GlaxoSmithKline Consumer Healthcare Pakistan's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GlaxoSmithKline Consumer Healthcare Pakistan's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GlaxoSmithKline Consumer Healthcare Pakistan Company Filings, last reported 6 months ago.

KASE:GSKCH Past Debt and Equity Data
Date (Data in PKR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 4,138.05 678.04 325.35
2019-06-30 3,858.53 800.16 42.66
2019-03-31 4,002.30 1,562.55 781.33
2018-12-31 3,834.99 1,591.78 707.44
2018-09-30 2,298.24 0.00 997.48
2018-06-30 2,148.04 0.00 1,152.52
2018-03-31 2,051.10 0.00 1,415.44
2017-12-31 2,296.83 0.00 1,301.55
2017-09-30
2017-06-30
2017-03-31 1,596.58 0.00 670.34
2016-12-31 1,596.58 0.00 670.34
2015-12-31 -0.25 0.00 0.00
  • GlaxoSmithKline Consumer Healthcare Pakistan's level of debt (16.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if GlaxoSmithKline Consumer Healthcare Pakistan's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (121.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 42x coverage).
X
Financial health checks
We assess GlaxoSmithKline Consumer Healthcare Pakistan's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GlaxoSmithKline Consumer Healthcare Pakistan has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is GlaxoSmithKline Consumer Healthcare Pakistan's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.55%
Current annual income from GlaxoSmithKline Consumer Healthcare Pakistan dividends.
If you bought PKR2,000 of GlaxoSmithKline Consumer Healthcare Pakistan shares you are expected to receive PKR51 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • GlaxoSmithKline Consumer Healthcare Pakistan's pays a lower dividend yield than the bottom 25% of dividend payers in Pakistan (2.69%).
  • GlaxoSmithKline Consumer Healthcare Pakistan's dividend is below the markets top 25% of dividend payers in Pakistan (9.2%).
Upcoming dividend payment

Purchase GlaxoSmithKline Consumer Healthcare Pakistan before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KASE:GSKCH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Asia Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 103 Stocks 1.6%
Pakistan Market Average Dividend Yield Market Cap Weighted Average of 214 Stocks 7.3%
Pakistan Minimum Threshold Dividend Yield 10th Percentile 1.5%
Pakistan Bottom 25% Dividend Yield 25th Percentile 2.7%
Pakistan Top 25% Dividend Yield 75th Percentile 9.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

KASE:GSKCH Past Annualized Dividends Data
Date (Data in PKR) Dividend per share (annual) Avg. Yield (%)
2019-04-02 5.000 2.237
2018-03-08 5.000 1.417
2018-01-29 5.000 1.124

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, GlaxoSmithKline Consumer Healthcare Pakistan has been paying a dividend for less than 10 years.
  • GlaxoSmithKline Consumer Healthcare Pakistan has only been paying a dividend for 2 years, and since then there has been no growth.
Current Payout to shareholders
What portion of GlaxoSmithKline Consumer Healthcare Pakistan's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.9x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess GlaxoSmithKline Consumer Healthcare Pakistan's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GlaxoSmithKline Consumer Healthcare Pakistan afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GlaxoSmithKline Consumer Healthcare Pakistan has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of GlaxoSmithKline Consumer Healthcare Pakistan's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sohail Matin
CEO Bio

Mr. Sohail Ahmed Matin serves as Chief Executive Officer and General Manager at GlaxoSmithKline Consumer Healthcare Pakistan Limited and GSK OTC (Pvt.) Ltd. Mr. Matin served as Director of Quality Assurance & Manufacturing Development of SmithKline Beecham. He served as Country Manager of Consumer Healthcare at GlaxoSmithKline Pakistan Limited and served as its General Manager of Consumer Healthcare until December August 22, 2016. Mr. Matin served as Area Regulatory & Business Development Director Middle East & Africa at SmithKline Beecham. Mr. Matin commenced his career with Glaxo Pakistan Limited in Supply Chain in 1986 and then moved to SK&F and Sterling Winthrop. He joined SmithKline Beecham in 1997. In GlaxoSmithKline, his biggest achievement was the turnaround of Consumer Healthcare Pakistan business, delivering a compound annual growth of 25% for the last six years. The key to his success was putting together a high performance team, significantly improving Glaxo Pakistan’s Commercial Execution capability and articulating and aligning everybody behind its high growth ambition (Vision 4X). He served as Director of GlaxoSmithKline Pakistan Limited until April 02, 2020. He serves as a Director at GlaxoSmithKline Consumer Healthcare Pakistan Limited. He served as a Non-Executive Director at GlaxoSmithKline Pakistan Limited since August 6, 2016 until August 30, 2016. He holds a Master’s degree in Mechanical Engineering from Stevens Institute of Technology, followed by an MBA in Management from Oklahoma State University.

CEO Compensation
  • Insufficient data for Sohail to compare compensation growth.
  • Insufficient data for Sohail to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Sohail Matin

TITLE
CEO & Director

Talal Ahmed

TITLE
CFO & Director
TENURE
1.5 yrs

Abdul Pirzada

TITLE
Head of Corporate Affairs and Administration

Sadia Nasir

TITLE
Sales Director

Shoaib Raza

TITLE
Head of Medical Detailing

Irfan Qureshi

TITLE
Head of Supply Chain

Mazhar Shams

TITLE
Head of Regulatory Affairs

Muzna Hussain

TITLE
Head of Internal Audit

Varisha Shahid

TITLE
Head of Internal Audit

Mashal Mohammad

TITLE
Company Secretary
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure of the GlaxoSmithKline Consumer Healthcare Pakistan board of directors in years:

2.4
Average Tenure
  • The average tenure for the GlaxoSmithKline Consumer Healthcare Pakistan board of directors is less than 3 years, this suggests a new board.
Board of Directors

Muhammad Zindah Mohajir

TITLE
Independent Chairman of the Board
TENURE
0.1 yrs

Sohail Matin

TITLE
CEO & Director

Talal Ahmed

TITLE
CFO & Director
TENURE
1.3 yrs

Emine Kaya

TITLE
Customer Supply Chain Director of Middle East Markets & Director
TENURE
3.6 yrs

Syed Mehmood

TITLE
Director
TENURE
3.6 yrs

Syed Azeem Naqvi

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PKR) Value (PKR)
X
Management checks
We assess GlaxoSmithKline Consumer Healthcare Pakistan's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GlaxoSmithKline Consumer Healthcare Pakistan has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan. It offers products in the areas of pain relief under the Panadol and Voltral brands; respiratory health under the Panadol CF, Sancos, T-Day, Tandegyl, and Actified brands; oral health under the Sensodyne and Parodontax brands; nutrition and gastrointestinal health under the CaC-1000 PLUS, Horlicks, ENO, and Qalsan D brands; and skin health under the Acne Aid, Duofilm, Brevoxyl, Hydrozole, Oilatum, Physiogel, SpectraBan, and SunBlock 60 brands. GlaxoSmithKline Consumer Healthcare Pakistan Limited also exports its products. The company was incorporated in 2015 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Consumer Healthcare Pakistan Limited is a subsidiary of Glaxosmithkline Consumer Healthcare B.V.

Details
Name: GlaxoSmithKline Consumer Healthcare Pakistan Limited
GSKCH
Exchange: KASE
Founded: 2015
PKR22,976,629,375
117,054,508
Website: http://www.pk-consumerhealthcare.gsk.com
Address: GlaxoSmithKline Consumer Healthcare Pakistan Limited
35, Dockyard Road,
West Wharf,
Karachi,
74000,
Pakistan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KASE GSKCH Ordinary Shares Pakistan Stock Exchange Limited PK PKR 22. Mar 2017
KASE GSKCH PKR10 Pakistan Stock Exchange Limited PK PKR 06. Apr 2020
Number of employees
Current staff
Staff numbers
480
GlaxoSmithKline Consumer Healthcare Pakistan employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 19:22
End of day share price update: 2020/04/06 00:00
Last earnings filing: 2019/10/31
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.